Division of Transfusion Medicine, Department of Haematology, University of Cambridge, Cambridge, UK.
Hepatology. 2010 Nov;52(5):1600-10. doi: 10.1002/hep.23886.
Genotype D occult hepatitis B virus (HBV) infections (OBIs) have a high frequency of amino acid substitutions in the major hydrophilic region of the small surface protein (S protein). This possibly reflects an escape mutation mechanism to evade detection by the host immune system. Mutations may also impact the detection of hepatitis B surface antigen (HBsAg) by commercial assays. To test these hypotheses, 20 recombinant HBV genotype D surface proteins from OBI carriers with or without antibody to hepatitis B surface antigen (anti-HBs) were expressed in yeast. Recombinant surface protein (rS protein) variants were nonreactive with autologous anti-HBs but reacted weakly with vaccine-induced anti-HBs supporting an immune escape mechanism. rS protein variants tested with a wide range of HBs antibodies, and HBsAg commercial assays showed significantly lower antigenic reactivity in anti-HBs carriers than in donors with antibody to hepatitis B core antigen (anti-HBc) only. Eight out of 10 recombinant variants from anti-HBs carriers reacted weakly or were nonreactive with antibodies to HBs as well as with qualitative and quantitative commercial HBsAg assays, whereas eight out of 10 anti-HBc-only plasmas were fully reactive. rS proteins with substitutions of wild-type cysteine at positions 121, 124, and 137 were nonreactive or showed poor reactivity. However, mutation of cysteine 147 did not alter reactivity compared with controls. Restoration of cysteines 124 and 137 by site-directed mutagenesis improved antigenic reactivity.
Escape mutation is a mechanism associated with OBI, which also leads to decreased reactivity in HBsAg detection assays. Performance of commercial assays would be improved by the incorporation of OBI mutants in reagent development.
基因型 D 隐匿性乙型肝炎病毒 (HBV) 感染 (OBI) 在小表面蛋白 (S 蛋白) 的主要亲水区域具有高频氨基酸替换。这可能反映了逃避宿主免疫系统检测的逃逸突变机制。突变也可能影响乙型肝炎表面抗原 (HBsAg) 的商业检测。为了验证这些假设,从具有或不具有乙型肝炎表面抗原抗体 (抗-HBs) 的 OBI 携带者中表达了 20 种重组 HBV 基因型 D 表面蛋白。重组表面蛋白 (rS 蛋白) 变体与自身抗-HBs 无反应,但与疫苗诱导的抗-HBs 弱反应,支持免疫逃逸机制。rS 蛋白变体与广泛的 HBs 抗体和 HBsAg 商业检测试剂进行了测试,结果显示在抗-HBs 携带者中,rS 蛋白变体的抗原反应性明显低于仅具有乙型肝炎核心抗原抗体 (抗-HBc) 的供体。10 个来自抗-HBs 携带者的重组变体中有 8 个与 HBs 抗体以及定性和定量的商业 HBsAg 检测试剂反应较弱或无反应,而 10 个抗-HBc 仅血浆均完全反应。在位置 121、124 和 137 处具有野生型半胱氨酸替换的 rS 蛋白无反应或反应性差。然而,与对照相比,半胱氨酸 147 的突变并未改变反应性。通过定点突变恢复半胱氨酸 124 和 137 可提高抗原反应性。
逃逸突变是与 OBI 相关的机制,它也导致 HBsAg 检测试验中的反应性降低。通过在试剂开发中纳入 OBI 突变体,商业检测试剂的性能将得到改善。